Recent recommendations emphasize the need to assess kidney function using creatinine-based predictive equations, in order to optimize the care of patients with chronic kidney disease (CKD). The most widely used equations are the Cockcroft-Gault (CG) and the simplified MDRD formulas. However, they still need to be validated in large samples of subjects, including large non-US cohorts. We compared renal clearance of 51 Cr-EDTA with glomerular filtration rate (GFR) estimated using either the However, analysis of subgroups defined by age, gender, BMI, and GFR level showed that the biases of the two formulas could be much larger in selected populations.
INTRODUCTION:
The prevalent and incident rates of end stage renal disease (ESRD) are continuously increasing in all Western countries. Data from the US Renal Data System predict that the number of patients registered with ESRD in 1997 will have doubled in 2010, leading to approximately 700 000 patients with ESRD and 2.2 million patients in 2030 (32), and similar trends are anticipated in other countries (27, 23, 14, 4, 22) . In order to level off these incident rates, various initiatives, such as the Kidney Disease Outcomes Quality Initiative (K/DOQI), have provided physicians with guidelines to optimize the care of patients with chronic kidney disease (CKD). These guidelines emphasize the need to assess kidney function using predictive equations rather than serum creatinine alone (25). However, they also highlight the fact that these equations still need to be validated in large samples of subjects, and in particular that they should be tested in non-US populations and in individuals with mild decrease in kidney function or normal GFR (25).
Validation of the predictive formulas is also particularly important for patients aged 65 and older, who have by far the highest incident rates of ESRD (27, 23, 14, 4, 22) .
The formulas that are most widely used to estimate kidney function, and that are recommended in adults by the K/DOQI guidelines (25), are the Cockcroft-Gault (CG) formula (8) and the recently developed (19) with previously diagnosed Chronic Kidney Disease (27, 23, 14, 4, 22) . The mean GFR in this population was 39.8 ± 21.2 mL/min /1.73m2 and the mean age of the cohort was 4 50.6 ± 12.7 years.
The K/DOQI CKD guidelines have established a five-stage classification of patients with CKD that is based solely on kidney function. These stages are defined by GFR ³ 90 mL/min/1.73m 2 (stage 1), 60 to 89 mL/min/1.73m 2 (stage 2), 30 to 59 mL/min/1.73m 2 (stage 3), 15 to 29 mL/min/1.73m 2 (stage 4), and <15 mL/min/1.73m 2 (stage 5), (25).
The guidelines state that the stage of kidney disease should be determined for each CKD patient, and that a clinical action plan should be developed based on the stage of disease (25). Thus, inaccurate estimation of kidney function may be responsible for misclassification of some patients and lead to inappropriate evaluation or treatment of these patients (13) . However, so far, few studies have assessed the applicability of the MDRD and CG formulas to large cohorts of subjects with wide ranges of renal function. One study compared various formulas with 125 I-iothalamate GFR, in a cohort of 1,703 African Americans with presumed hypertensive nephrosclerosis and mean serum creatinine levels of 1.85 ± 0.88 mg/dL (27, 23, 14, 4, 22) . All other studies focused on much smaller cohorts of subjects with or without CKD (27, 23, 14, 4, 22) .
Furthermore, with one exception (14) , no particular attention was paid to calibration of serum creatinine measurements, while this has been shown to be of critical importance for subjects with normal or near normal serum creatinine values (10, 9) .
In this study, we compare renal clearance of 51 Cr-EDTA (measured GFR) with GFR estimated by the CG formula (CG GFR) or the MDRD equation (MDRD GFR) in a cohort of 2,095 European subjects. Our findings support the preferential use of the MDRD formula, but raise caution regarding its usage in some subgroups of subjects such as young adults with normal renal function or stage 2 CKD or underweight subjects.
5

MATERIALS AND METHODS
Patient selection
Records of all patients referred to our Department of Physiology between January 1990 and April 2004 in order to perform GFR measurements were retrospectively reviewed. For patients who had more than one GFR measurement, only the first one was considered. Renal transplant patients and subjects under 18 years of age were excluded. Among the remaining 2,178 independent patients, only 83 were black. Since ethnicity is one of the determinants of the MDRD equation, we decided to exclude black patients and restrict the analysis to the 2,095 non-black individuals, in order to ensure statistical relevance of the study. Among them, 1,933 had CKD and 162 were healthy potential kidney donors.
GFR measurements
Renal clearance of 51 Cr-EDTA was determined as previously described (27, 23, 14, 4, 22) . Briefly, 3.5 MBq of 51 Cr-EDTA (Amersham Health SA) were injected intravenously as a single bolus. The injected dose was reduced to 1.8 MBq in patients with an estimated GFR derived from the CG formula of less than 30 mL/min and in case of body weight lower than 40 kg. After allowing one hour for distribution of the tracer in the extracellular fluid, urine was collected and discarded. Then, average renal 51 Cr-EDTA clearance was determined on five consecutive 30-min clearance periods. Blood was drawn at the midpoint of each clearance period and up to 300 min after injection.
The radioactivity measurements in 1-ml plasma and urine samples were carried out on a 3-inch crystal gamma-ray well counter (Packard Cobra, Alberta, MN 
Creatinine assay
All creatinine measurements were performed in the same laboratory. Blood samples were obtained simultaneously with the GFR measurement. A modified kinetic Jaffé colorimetric method was used with a Bayer RA-XT and a Konelab 20 analyzer. A five point calibration was applied in each assay. Prior to measurement, ultrafiltration of plasma through a 20 kDa cut-off membrane (MPS-1, Amicon, Beverly, MA) was performed in order to discard chromogens linked to albumin and other heavy proteins.
In the absence of an international standard for creatinine assay, the linearity of the measurements was verified by using plasma samples from normal subjects in which increasing amounts of desiccated creatinine hydrochloride (MW 149.6; Sigma Chemicals, Perth, Australia) had been added.
Linear regression analysis showed that the slope of the relationship between measured and expected creatinine concentrations was1.008 ± 0.006 (95% confidence interval 0.997 -1.020) and that the Y-intercept was 0.014 ± 0.013 (95% confidence interval -0.013 -0.041), (Figure 1 
Creatinine based estimation of GFR
The two formulas that we studied in order to predict GFR from serum creatinine were the one proposed by Cockcroft Where PCr is plasma creatinine concentration.
A correction for body surface area was necessary for CG formula. This was performed using estimated BSA according to Du Bois ( The combined root mean square error (CRMSE) was examined. CRMSE is calculated as the square root of [(mean difference between estimated and measured GFR) 2 + (SD of the difference) 2 ]. It measures both bias and precision (27, 23, 14, 4, 22) .
Statistical analyses were performed using Statview 5.0 software (SAS, Cary, NC) 9
RESULTS
Demographics and GFR distribution.
The main characteristics of the study population are shown in 
Relationships between creatinine-based estimations of GFR and measured
GFR
The relationships between measured GFR and MDRD GFR or CG GFR are depicted in Figure 3B ), which is highly statistically significant (p < 0.0001) but has limited clinical implications. However, for both formulas, the biases were not uniform over the whole range of GFR values (Table 2A) . (Table 2A) . For all categories of GFR, the MDRD formula was more precise than the CG one (Table 2A) .
Accuracy is a global indicator of the performance of a formula, that takes into account its bias and its precision. We tested the accuracy of both formulas in subjects with measured GFR higher and lower than 60 mL/min/1.73m 2 by calculating CRMSE and by determining the percentage of subjects not deviating from more than 15, 30 and 50% from measured GFR (Accuracy within in Table 2B ). In all cases, and with both measurements of accuracy, the MDRD formula had better performances than the CG one (Table 2B) .
Since, the performance of a regression-based equation depends on the population the 11 equation is applied to, we tested the performance of the equations in CKD patients and in kidney donors (Table 3A and 3B). We also assessed the sensitivity and specificity of the two formulas for assigning CKD patients to the categories defined by the KDOQI CKD classification (Table 3A ) (25). Performance of the MDRD equation was slightly but not significantly better in kidney donors (Table 3B ) than in stage 1 or 2 CKD patients (Anova, p = 0.49, NS). The CG formula was less biased in stage 1 or 2 CKD patients than in kidney donors (Anova, p = 0.001).
Comparison of bias and precision of estimated GFR values according to gender and age
Besides plasma creatinine values, gender, age and weight are the three parameters that are taken into account in the MDRD and/or CG formulas. We thus analyzed the performance of these two formulas according to age, gender, and BMI. As a first step, we focused on gender and age, since these parameters are used in both formulas.
Biases of the MDRD and CG formulas with respect to gender and in two different age groups are shown in Figure 4 . A cut-off age of 65 years was chosen, since data from the United States Renal Data System show that the incident rates of ESRD are more than two-fold higher in subjects 65 years or older than in younger ones (32). The bias of the MDRD formula was very small in all subgroups, except for female under 65 years of age (bias: -3.1 ± 17.2 mL/min/1.73m 2 ), while the biases of the CG formula were always significantly larger (p < 0.0001).
The precision, and accuracy of the two formulas according to gender and age are reported in Figures 5A and 5B) . In all cases, the MDRD formula was at least as accurate as the CG one. The CG formula principally lacked accuracy in subjects younger than 65 years and with GFR values <60 mL/min/1.73m 2 while the accuracy of the MDRD formula was much more uniform ( Figure 5B ).
Comparison of bias and precision of estimated GFR values according to body mass index
The cohort was divided into four standard subgroups according to body mass index 32.2, and 52.2 ± 31.5 mL/min/1.73m 2 from underweight to overweight subjects, respectively, p < 0.0001). As shown in figure 6 , the MDRD formula largely overestimated kidney function in underweight subjects; the bias observed for this subgroup (12.2 ± 24.8 mL/min/1.73m 2 ) being significantly higher than the one 13 observed for all other classes of BMI (p < 0.0001 by ANOVA test). In all other subgroups, the MDRD formula was less biased, more precise and more accurate than the CG one ( Figure 6 ).
Consequences of the limitations of the MDRD and Cockcroft formulas on the K/DOQI CKD classification
The K/DOQI guidelines recommend to define a clinical action plan for each patient with CKD, based on the stage of disease as defined by the K/DOQI CKD classification (25). Therefore, we evaluated the consequences of the limitations of the MDRD and CG formulas on the classification of CKD patients (Table 5A ). This analysis was based solely on results of GFR determinations and all 2,095 subjects were considered, whether or not they had kidney damage. For subjects with GFR ³ 90 mL/min/1.73m 2 , the CG formula was slightly more accurate than the MDRD one, but for all other GFR levels, more subjects were classified in the proper stage by the MDRD formula than by the CG one (Table 5A) . Overall, only 70.8% and 67.6% of subjects were classified in the correct stage by the MDRD and CG formulas, respectively. Using the average values of both formulas to estimate GFR did not improve the accuracy of the prediction (Table   5B ). The consequences of the limitations of the formulas can also be depicted by a figure plotting prediction intervals of measured GFR as a function of estimated GFR ( Figure 7 ).
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DISCUSSION
In this study, we evaluated the performances of the CG and MDRD formulas for estimating GFR, in a cohort of 2,095 subjects. As recommended by the K/DOQI guidelines, these two formulas are increasingly used in daily clinical practice and decisions regarding the care of CKD patients are based on estimated GFR, but their accuracy is still debated (20) .
An important characteristics of our cohort is that it included subjects whose measured GFR ranged from 2.3 to 166.4 mL/min/1.73m 2 (IQR: 33.6 -87.3 mL/min/1.73m 2 ), with similar numbers of subjects having measured GFR values above and below 60 mL/min/1.73m 2 (1,044 and 1,051 subjects, respectively). Thus, the performances of the CG and MDRD formulas could be assessed over a wide range of kidney function.
Furthermore, since the vast majority of patients included in this study were Europeans the performances of the MDRD and CG formulas could be assessed in a group of subjects whose anthropometric characteristics are slightly different from those of Americans. For example, when compared to the MDRD cohort (27, 23, 14, 4, 22) , the mean weight of our study population was 11.2% lower (70.7 ± 15.3 kg versus 79.6 ± 16.8 kg), and the mean body surface area was 6.3% lower (1.79 ± 0.21 kg/m 2 versus 1.91 ± 0.23 kg/m 2 ), while on average our patients were only 2.2 years older than those included in the MDRD cohort (52.8 ± 16.5 years versus 50.6 ± 12.7 years) and while a similar percentage of subjects were male in both cohorts (59% versus 60%).
Recent studies have emphasized the importance of careful calibration of serum creatinine measurements to reliably estimate GFR in patients with normal or near normal renal function, using creatinine-based equations (10, 9) . In the absence of international standard, we have used 15 plasma samples supplemented with precise amounts of creatinine hydrochloride to calibrate our assay. Analysis of the relationship between expected and measured creatinine concentration strongly suggests that our assay reliably measures creatinine concentrations. The relationship between measured and expected creatinine concentrations was linear over a wide range of values, and not different from the identity line. Furthermore, in our population, the ratio of MDRD GFR over measured GFR did not vary over time, which suggests that no calibration bias occurred over time. This careful calibration of plasma creatinine measurements may explain that, for subjects with normal or near normal kidney function, we found much less differences between estimated and measured GFR than in other studies (27, 23, 14, 4, 22) .
In this study, GFR was measured by renal clearance of 51 Cr-EDTA, while renal clearance of 125 Iiothalamate has been used by studies in North America. However, the performance of our method
is similar to what has been reported for iothalamate clearance (26) .
Analysis of bias, a measure of systematic error, in the entire study population showed a very good global agreement between estimated and measured GFR for each of the two formulas. On average, estimated GFR was only 1.0 mL/min/1.73m 2 lower than measured GFR with the MDRD formula and 1.9 mL/min/1.73m 2 higher with the CG formula. A similar bias has been observed when the CG formula was compared to GFR measured by 125 I-iothalamate clearance in all patients screened for the AASK study; the mean difference between estimated and measured GFR being -2.7 mL/min/1.73m 2 (27, 23, 14, 4, 22) . In contrast, in the MDRD cohort, the CG formula was shown to largely overestimate measured GFR (19) . The reasons for this discrepancy are not clear, but it may be due to differences in patients characteristics.
When estimating the performance of a formula, precision is probably more important than bias. Our study showed that both the MDRD and CG formulas largely lack precision. Previous studies focusing on patients with or without CKD have already
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highlighted the global lack of precision of these two formulas (27, 23, 14, 4, 22) .
However, in our analysis their performances were quite different in various subgroups of subjects. The greatest lack of precision was observed for subjects less than 65 years with measured GFR above 60 mL/min/1.73m 2 , for underweight subjects, and, in the case of the CG formula, for obese subjects.
Analysis of the ability of a formula to classify patients in different subgroups depends on the characteristics of the population. In particular, it depends on the proportion of patients who happen to be near the boundaries of the subgroups. In our series, analysis of the performance of both formulas to classify patients according to the K/DOQI CKD classification showed that only 70.8% of subjects were classified in the proper category when using the MDRD formula and 67.6% when using the CG one, which clearly highlights the limitations of both formulas. For example, when using the CG and the MDRD formulas, 28.8% and 16.7% of stage 4 CKD patients were misclassified as stage 3 CKD patients, respectively, which could introduce undue delays in the preparation for renal replacement therapy. By contrast, about 20% of subjects with measured GFR ³ 60 mL/min /1.73m 2 were classified as having stage 3 CKD with both formulas, which could lead to unnecessary assessment of CKD-related complications. Use of the average of the two formulas did not decrease the misclassification rate, which answers to one the K/DOQI research recommendations (25). In order not to be misled by the use of the formulas when taking care of individual CKD patients, it is probably important to keep in mind the width of the prediction interval for GFR associated with each value of estimated GFR ( Figure 7 ).
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In conclusion, in a study population of 2,095 European subjects, the MDRD formula provided more reliable estimations of kidney function than the CG formula. However, both formulas lacked precision, and using either one of them for defining the stage of disease according to the K/DOQI CKD classification would have led to inappropriate staging of about 30% of subjects. 
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(58.7)
Bias is defined as the mean difference between Estimated and Measured GFR. Precision is one standard deviation of bias. Bias is defined as the mean difference between Estimated and Measured GFR. Precision is one standard deviation of bias. Accuracy was assessed by determining the percentage of subjects not deviating from more than 15, 30 and 50% from measured GFR, and by calculating the combined root mean square error (CRMSE). Bias is defined as the mean difference between Estimated and Measured GFR. Precision is one standard deviation of bias. 
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